GlassScriptPhysician profile
Christine Horrigan
NPI 1093481574
$1,245.14
in general payments reported to CMS, 2019-2025
11 companies · $47.22 in 2025
The $47.22 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $53.07 · 2022: $474 · 2023: $374 · 2024: $297 · 2025: $47.22.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $718.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $717.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $436.67 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $229.33 | 2023-2024 | Ilumya |
| Lilly USA, LLC | $215.33 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $120.24 | 2022-2024 | Sotyktu |
| Janssen Biotech, INC. | $73.06 | 2022-2023 | Tremfya, Simponi Aria, Remicade |
| Novartis Pharmaceuticals Corporation | $45.81 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $42.94 | 2022 | |
| Arcutis Biotherapeutics, INC. | $28.95 | 2024 | Zoryve |
| Incyte Corporation | $24.37 | 2023 | Opzelura |
| Celgene Corporation | $16.26 | 2024 | Sotyktu |
| Galderma Laboratories, L.P. | $12.18 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christine Horrigan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.